Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
The DOI matches its Crossref record; 23 of the 26 references it cites were found in a registry or an index.
Abstract
We analyzed data from the National Nosocomial Infections Surveillance (NNIS) System from 1986-2003 to determine the epidemiology of gram-negative bacilli in intensive care units (ICUs) for the most frequent types of hospital-acquired infection: pneumonia, surgical site infection (SSI), urinary tract infection (UTI), and bloodstream infection (BSI). We analyzed >410,000 bacterial isolates associated with hospital-acquired infections in ICUs during 1986-2003. In 2003, gram-negative bacilli were associated with 23.8% of BSIs, 65.2% of pneumonia episodes, 33.8% of SSIs, and 71.1% of UTIs. The percentage of BSIs associated with gram-negative bacilli decreased from 33.2% in 1986 to 23.8% in 2003. The percentage of SSIs associated with gram-negative bacilli decreased from 56.5% in 1986 to 33.8% in 2003. The percentages pneumonia episodes and UTIs associated with gram-negative bacilli remained constant during the study period. The proportion of ICU pneumonia episodes associated with Acinetobacter species increased from 4% in 1986 to 7.0% in 2003 (P<.001, by the Cochran-Armitage chi2 test for trend). Significant increases in resistance rates were uniformly seen for selected antimicrobial-pathogen combinations. Gram-negative bacilli are commonly associated with hospital-acquired infections in ICUs. The proportion of Acinetobacter species associated with ICU pneumonia increased from 4% in 1986 to 7.0% in 2003.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a group, these organisms are the most common etiology of nosocomial infections, including most cases of hospital-acquired pneumonia, ventilator-associated pneumonia and healthcare-associated pneumonia, and they are important causes of morbidity and death in hospitalized patients (1).”
From Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia (2017) · cites this paper as [1]
Citations
Cites
Vincent, J.-L. (1995) · JAMA · doi:10.1001/jama.1995.03530080055041 · Cited by 1,632 · cited 1×
“A recent review by Archibald [9] showed that the types of pathogens encountered in health care institutions in North America, Europe, Asia, Australia, and even Africa are, for the most part, similar [10-14].”
Hospital Epidemiology and Infection Control
Mayhall, C. G. (2011) · Cited by 1,179
National nosocomial infections surveillance system (NNIS): Description of surveillance methods
Emori, T. G., Culver, D. H., Horan, T. C., Jarvis, W. R., White, J. W., Olson, D. R., Banerjee, S., Edwards, J. R., Martone, W. J., Gaynes, R. P., et al. (1991) · American Journal of Infection Control · doi:10.1016/0196-6553(91)90157-8 · Cited by 832
Self-citationSurveillance nosokomialer Infektionen
Gastmeier (2004) · Therapeutische Umschau · doi:10.1024/0040-5930.61.3.204 · Cited by 509
Epidemiology and control of nosocomial infections in adult intensive care units
Weinstein, R. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90366-6 · Cited by 300 · cited 1×
“the 4 most frequent types of hospital-acquired infection: pneumonia, surgical site infection (SSI), urinary tract infection (UTI), and bloodstream infection (BSI) [1].”
BackgroundSelf-citationMultidrug-Resistant Acinetobacter baumannii
Abbo, A., Navon-Venezia, S., Hammer-Muntz, O., Krichali, T., Siegman-Igra, Y., & Carmeli, Y. (2005) · Emerging Infectious Diseases · doi:10.3201/eid1101.040001 · Cited by 285 · cited 1×
“Acinetobacter organisms are intrinsically resistant to many antimicrobials and can acquire resistance to others [7].”
BackgroundHOSPITAL ACQUIRED INFECTIONS: KNOWLEDGE ABOUT IT AND ITS PREVENTION
QAYYUM, S., WAQAS, B., & SATTAR, A. (2010) · The Professional Medical Journal · doi:10.29309/tpmj/2010.17.02.2211 · Cited by 256
MAGNITUDE AND PREVENTION OF NOSOCOMIAL INFECTIONS IN THE INTENSIVE CARE UNIT
Fridkin, S. K., Welbel, S. F., & Weinstein, R. A. (1997) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70366-4 · Cited by 225 · cited 1×
“A recent review by Archibald [9] showed that the types of pathogens encountered in health care institutions in North America, Europe, Asia, Australia, and even Africa are, for the most part, similar [10-14].”
BackgroundSelf-citationStreit, J. M., Jones, R. N., Sader, H. S., & Fritsche, T. R. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.12.019 · Cited by 191
Syncope and orthostatic hypotension
Atkins, D., Hanusa, B., Sefcik, T., & Kapoor, W. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90012-m · Cited by 172
Research works printed but not linked: 2
- 1991, The American journal of medicine, 91, 86
- Richards, 2003, Annals of surgery, 237, 358, 10.1097/00000658-200303000-00009 · doi:10.1097/00000658-200303000-00009
Cited by
Items 201–300 of 1,000
Talaat, M., Hafez, S., Saied, T., Elfeky, R., El‐Shoubary, W., & Pimentel, G. (2009) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.06.011 · Cited by 84
“Recently published nosocomial surveillance studies conducted in ICUs in North America and Europe consistently support E coli, P aeruginosa, and enterococci as the predominant bacterial pathogens from UTI.(9,29) These findings are comparable with our study in which 34.”
InfluentialDrug Treatment for Multidrug-Resistant Acinetobacter Baumannii Infections
Bassetti, M., Righi, E., Esposito, S., Petrosillo, N., & Nicolini, L. A. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.649 · Cited by 84
Liu, Q., Li, X., Li, W., Du, X., He, J., Tao, C., & Feng, Y. (2015) · Scientific Reports · doi:10.1038/srep11715 · Cited by 84
Shuman, E. K., & Chenoweth, C. E. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e6ce8f · Cited by 83
Acinetobacterinfections: a growing threat for critically ill patients
Falagas, M. E., Karveli, E. A., Siempos, I. Ι., & Vardakas, K. Z. (2007) · Epidemiology and Infection · doi:10.1017/s0950268807009478 · Cited by 82
“2003 Gaynes [33] Surveillance Nationwide USA All types n.”
Kurosu, M., Narayanasamy, P., Biswas, K., Dhiman, R. K., & Crick, D. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070638m · Cited by 82
Penicillin-Binding Protein 3 Is Essential for Growth of Pseudomonas aeruginosa
Chen, W., Zhang, Y., & Davies, C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-16 · Cited by 94
“cancer, and AIDS, as well as recipients of organ transplants (4).”
BackgroundThe impact of human vaccines on bacterial antimicrobial resistance. A review
Jansen, K. U., Gruber, W. C., Simon, R., Wassil, J., & Anderson, A. S. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01274-z · Cited by 88
Pereira, G. H., Müller, P. R., & Levin, A. S. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.01.008 · Cited by 81
Shrestha, A. K., Bajracharya, A. M., Subedi, H., Turha, R. S., Kafle, S., Sharma, S., Neupane, S., & Chaudhary, D. K. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2917-x · Cited by 93
Pillar, C. M., Torres, M. K., Brown, N. P., Shah, D., & Sahm, D. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00381-08 · Cited by 79
“Gram-negative bacilli play a significant role in the most prevalent types of nosocomial infections including hospitalacquired pneumonia, ventilator-associated pneumonia, urinary tract infections, and intra-abdominal infections ( 7 , 31, 32).”
BackgroundRole of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia
Morris, A. E., Liggitt, H. D., Hawn, T. R., & Skerrett, S. J. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00155.2009 · Cited by 79
Salm, F., Deja, M., Gastmeier, P., Kola, A., Hansen, S., Behnke, M., Gruhl, D., & Leistner, R. (2016) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-016-0157-9 · Cited by 79
Melo, A., Gomes, A. D. M., de Melo, F. L., Ardisson-Araújo, D. M. P., de Vargas, Á. C., Ely, V. L., Kitajima, E. W., Ribeiro, B. M., & Wolff, J. L. C. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1481-z · Cited by 89
Monotherapy or Combination Therapy? The Pseudomonas aeruginosa Conundrum
Traugott, K. A., Echevarria, K. L., Maxwell, P. R., Green, K., & Lewis, J. S. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.598 · Cited by 80
Nhu, N. T. K., Lan, N. P. H., Campbell, J. I., Parry, C. M., Thompson, C. N., Tuyen, H. T., Hoàng, N. V. M., Tam, P. T. T., Le, V. M., Nga, T. V. T., et al. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.076646-0 · Cited by 78
“In Europe and the USA, the principal organism associated with VAP is Staphylococcus aureus (Chastre et al., 2014; Gaynes & Edwards, 2005; Joseph et al., 2010; Lee et al., 2013).”
BackgroundNephrotoxicity Associated with Intravenous Colistin in Critically Ill Patients
Doshi, N., Mount, K. L., & Murphy, C. V. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1257 · Cited by 78
Aoyagi, T., Newstead, M. W., Zeng, X., Nanjo, Y., Peters-Golden, M. L., Kaku, M., & Standiford, T. J. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006737 · Cited by 77
Oostdijk, E. A. N., de Smet, A. M. G. A., Kesecioglu, J., & Bonten, M. J. M. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318208ee26 · Cited by 77
“Gram-negative bacteria (GNB) cause approximately 30% of all episodes of ICUacquired bacteremia (2), and they have been associated with increased morbidity and mortality (3).”
BackgroundGram‐Negative Bacteremia upon Hospital Admission: When Should Pseudomonas aeruginosa Be Suspected?
Schechner, V., Junior, V. A. N., Kaye, K. S., Leshno, M., Giladi, M., Rohner, P., Harbarth, S., Anderson, D. J., Karchmer, A. W., Schwaber, M. J., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596709 · Cited by 85
“hospital stay [1].”
Repurposing Anti-diabetic Drugs to Cripple Quorum Sensing in Pseudomonas aeruginosa
Hegazy, W. A. H., Khayat, M. T. A., Ibrahim, T. S., Nassar, M. S., Bakhrebah, M. A., Abdulaal, W. H., Alhakamy, N. A., & Bendary, M. M. (2020) · Microorganisms · doi:10.3390/microorganisms8091285 · Cited by 77
(2007) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-007-0337-0 · Cited by 96
Lonergan, Z. R., Nairn, B. L., Wang, J., Hsu, Y.-P., Hesse, L. E., Beavers, W. N., Chazin, W. J., Trinidad, J. C., VanNieuwenhze, M. S., Giedroc, D. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.089 · Cited by 76
Dortch, M. J., Fleming, S. B., Kauffmann, R. M., Dossett, L. A., Talbot, T. R., & May, A. K. (2010) · Surgical Infections · doi:10.1089/sur.2009.059 · Cited by 76
Photoinactivation of ESKAPE Pathogens: Overview of Novel Therapeutic Strategy
Nakonieczna, J., Woźniak, A., Pierański, M. K., Rapacka-Zdończyk, A., Ogonowska, P., & Grinholc, M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0329 · Cited by 76
Aconitate decarboxylase 1 is a mediator of polymicrobial sepsis
Wu, R., Liu, J., Wang, N., Zeng, L., Yu, C., Chen, F., Wang, H., Billiar, T. R., Jiang, J., Tang, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2028 · Cited by 72
Shen, F., Han, Q., Xie, D., Fang, M., Zeng, H., & Deng, Y. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.08.009 · Cited by 76
Next generation of antimicrobial peptides as molecular targeted medicines
Aoki, W., Kuroda, K., & Ueda, M. (2012) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2012.05.001 · Cited by 81
Wallace, S. J., Li, J., Nation, R. L., Prankerd, R. J., Velkov, T., & Boyd, B. J. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp100458x · Cited by 76
Zheng, R., Zhang, Q., Guo, Y., Feng, Y., Liu, L., Zhang, A., Zhao, Y., Yang, X., & Xia, X. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0124-6 · Cited by 81
Gorityala, B. K., Guchhait, G., Goswami, S., Fernando, D. M., Kumar, A., Zhanel, G. G., & Schweizer, F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00867 · Cited by 75
Banerjee, T., Mishra, A., Das, A., Sharma, S., Barman, H., & Yadav, G. (2018) · Journal of Pathogens · doi:10.1155/2018/9129083 · Cited by 74
Moellering, R. C., Graybill, J. R., McGowan, J. E., & Corey, L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.001 · Cited by 84
Liu, Q., Li, W., Du, X., Li, W., Zhong, T., Tang, Y., Feng, Y., Tao, C., & Xie, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130701 · Cited by 74
Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections
Alexandre, Y., Berre, R. L., Barbier, G., & Blay, G. L. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-107 · Cited by 73
“1%, this pathogen thus becoming the main cause of acute respiratory infections [1].”
BackgroundMechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
J. Wolter, D., & D. Lister, P. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213804070311 · Cited by 72
Dwivedi, G. R., Maurya, A., Yadav, D. K., Khan, F., Darokar, M. P., & Srivastava, S. K. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12491 · Cited by 73
“coli predominates in case of urinary tract infections (6).”
BackgroundAnalytic Reviews: Prevention of Central Venous Catheter Bloodstream Infections
Walz, J. M., Memtsoudis, S. G., & Heard, S. O. (2010) · Journal of Intensive Care Medicine · doi:10.1177/0885066609358952 · Cited by 73
Qiu, H., KuoLee, R., Harris, G., & Chen, W. (2009) · Infection and Immunity · doi:10.1128/iai.01029-08 · Cited by 71
“Acinetobacter baumannii infection has recently emerged as a major cause of both community-associated and nosocomial infections worldwide ( 6 , 7). The overall 30-day mortality of Acinetobacter infection can be as high as 49%, with the respiratory tract being an important portal of entry (12).”
BackgroundSynergy of clavine alkaloid ‘chanoclavine’ with tetracycline against multi-drug-resistant E. coli
Dwivedi, G. R., Maurya, A., Yadav, D. K., Singh, V., Khan, F., Gupta, M. K., Singh, M., Darokar, M. P., & Srivastava, S. K. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1458654 · Cited by 72
Wang, C., Li, P., Niu, W., Yuan, X., Liu, H., Huang, Y., An, X., Fan, H., Zhangxiang, L., Mi, L., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2019.01.003 · Cited by 75
Resistant gram-negative bacilli: A neglected healthcare crisis?
Lautenbach, E., & Polk, R. E. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070477 · Cited by 82
Andriamanantena, T. S., Ratsima, E. H., Rakotonirina, H. C., Randrianirina, F., Ramparany, L., Carod, J.-F., Richard, V., & Talarmin, A. (2010) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-9-17 · Cited by 71
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Emerging infectious diseases · doi:10.3201/eid1411.080337 · Cited by 71
“aeruginosa infections, consistent with others’ observations, has remained relatively stable over the 6-year period (15).”
Kollef, M. H., Napolitano, L. M., Solomkin, J. S., Wunderink, R. G., Bae, I., Fowler, V. G., Balk, R. A., Stevens, D. L., Rahal, J. J., Shorr, A. F., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590937 · Cited by 69
“In an accompanying overview, the importance of the classification of HAIs was emphasized in terms of identifying a group of patients who would potentially benefit from initial treatment with broad-spectrum antibiotics [9].”
BackgroundMarschall, J., Agniel, D. M., Fraser, V. J., Doherty, J., & Warren, D. K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn104 · Cited by 78
Biofilm-Based Infections in Long-Term Care Facilities
Donelli, G., & Vuotto, C. (2014) · Future Microbiology · doi:10.2217/fmb.13.149 · Cited by 79
Curtailing Quorum Sensing in Pseudomonas aeruginosa by Sitagliptin
Abbas, H. A., Shaldam, M. A., & Eldamasi, D. (2020) · Current Microbiology · doi:10.1007/s00284-020-01909-4 · Cited by 70
Catalytic antimicrobial therapy using nanozymes
Wang, Q., Jiang, J., & Gao, L. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1769 · Cited by 69
De-escalation therapy in ventilator-associated pneumonia
Niederman, M. S. (2006) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000244126.84989.a2 · Cited by 69
Vincenti, S., Quaranta, G., Meo, C. D., Bruno, S., Ficarra, M. G., Carovillano, S., Ricciardi, W., & Laurenti, P. (2014) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2014.08.041 · Cited by 73
Stress Responses in the Opportunistic Pathogen Acinetobacter Baumannii
Fiester, S. E., & Actis, L. A. (2013) · Future Microbiology · doi:10.2217/fmb.12.150 · Cited by 77
Consales, G., Gramigni, E., Zamidei, L., Bettocchi, D., & Gaudio, A. R. D. (2011) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.12.016 · Cited by 68
“The reported incidence of institutional outbreaks has substantially increased during the past decades particularly in ICUs [12].”
BackgroundLandscape of Multidrug-Resistant Gram-Negative Infections in Egypt: Survey and Literature Review
El‐Kholy, A., El‐Mahallawy, H. A., Elsharnouby, N. M., Aziz, M. A. A., Helmy, A. M., & Kotb, R. E. M. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s298920 · Cited by 68
Teixeira, L. M., & Merquior, V. L. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-38922-1_245 · Cited by 68
Guidelines for the prevention of the intravascular catheter‐related infections
(2003) · Nutrition in Clinical Practice · doi:10.1177/0115426503018001105e · Cited by 68
Joo, E., Kang, C., Ha, Y. E., Kang, S., Park, S. Y., Chung, D. R., Peck, K. R., Lee, N. Y., & Song, J. (2011) · Microbial Drug Resistance · doi:10.1089/mdr.2010.0170 · Cited by 67
Ojdana, D., Sacha, P., Wieczorek, P., Czaban, S. L., Michalska‐Falkowska, A., Jaworowska, J., Jurczak, A., Poniatowski, B., & Tryniszewska, E. A. (2014) · International Journal of Antibiotics · doi:10.1155/2014/935842 · Cited by 66
“Bacteria belonging to theEnterobacteriaceae family have been reported worldwide as etiologic factors of many nosocomial infections [1].”
BackgroundHattemer, A., Hauser, A. R., Diaz, M. H., Scheetz, M. H., Shah, N. S., Allen, J. P., Porhomayon, J., & El-Solh, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02467-12 · Cited by 66
Potentiating aminoglycoside antibiotics to reduce their toxic side effects
Rosenberg, C. R., Fang, X. D., & Allison, K. R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237948 · Cited by 77
Volling, C., Ahangari, N., Bartoszko, J. J., Coleman, B. L., Jeldes, F. G., Jamal, A. J., Johnstone, J., Kandel, C. E., Kohler, P. P., Maltezou, H. C., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa590 · Cited by 65
Bosco, J. A., Tejada, P. R. R., Catanzano, A. A., Stachel, A. G., & Phillips, M. (2015) · The Journal of Arthroplasty · doi:10.1016/j.arth.2015.09.051 · Cited by 68
Qiu, H., KuoLee, R., Harris, G., & Chen, W. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.06.003 · Cited by 65
“baumannii is an emerging bacterial pathogen, which rapidly develops multiple drug resistance and is responsible for an increasing incidence of nosocomial pulmonary infections [1,2,4].”
Walkty, A. J., DeCorby, M. R., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01696-10 · Cited by 65
Acinetobacter baumannii: An Emerging and Important Pathogen.
Alsan, M. M., & Klompas, M. (2010) · PubMed · Cited by 65
Cassir, N., Thomas, G., Hraiech, S., Brunet, J., Fournier, P., Scola, B. L., & Papazian, L. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2015.02.010 · Cited by 67
Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., LaRocco, M., Gentry, L. O., Lolans, K., Quinn, J. P., & Garey, K. W. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01674.x · Cited by 71
“aeruginosa was the most commonly isolated Gram-negative species causing nosocomial pneumonia, and the third most commonly isolated Gram-negative species causing nosocomial urinary tract infection in the USA [1].”
BackgroundSulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis
Chu, H., Zhao, L., Wang, M., Liu, Y., Gui, T., & Zhang, J. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.10.029 · Cited by 64
Cheon, S., Kim, M.-J., Yun, S.-J., Moon, J. Y., & Ys, K. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.178 · Cited by 64
Dey, P., Fabri-Faja, N., Calvo-Lozano, O., Terborg, R. A., Belushkin, A. A., Yesilköy, F., Fàbrega, A., Ruiz‐Rodríguez, J. C., Ferrer, R., González‐López, J. J., et al. (2018) · ACS Sensors · doi:10.1021/acssensors.8b00789 · Cited by 64
Valentin, J. D. P., Straub, H., Pietsch, F., Lemare, M., Ahrens, C. H., Schreiber, F., Webb, J. S., van der Mei, H. C., & Ren, Q. (2021) · The ISME Journal · doi:10.1038/s41396-021-01157-9 · Cited by 70
“INTRODUCTION Infections caused by the opportunistic pathogen Pseudomonas aeruginosa are among the most prevalent and difficult to treat [1, 2].”
BackgroundYokoyama, Y., Matsumoto, K., Ikawa, K., Watanabe, E., Shigemi, A., Umezaki, Y., Nakamura, K., Ueno, K., Morikawa, N., & Takeda, Y. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.012 · Cited by 68
“Introduction 43 Acinetobacter baumannii is a significant global nosocomial pathogen [1] that 44 has been associated with hospital-acquired infections including pneumonia, surgical site 45 infection, urinary tract infections, and blood stream infections [2].”
BackgroundDiversity Within the O-linked Protein Glycosylation Systems of Acinetobacter Species
Scott, N. E., Kinsella, R. L., Edwards, A. V. G., Larsen, M. R., Dutta, S. M., Saba, J. A., Foster, L. J., & Feldman, M. F. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.038315 · Cited by 63
Antimicrobial Resistance among and Therapeutic Options against Gram‐Negative Pathogens
Rahal, J. J. (2009) · Clinical Infectious Diseases · doi:10.1086/599810 · Cited by 63
Russo, T. A., Page, M. G. P., Beanan, J. M., Olson, R., Hujer, A. M., Hujer, K. M., Jacobs, M. R., Bajaksouzian, S., Endimiani, A., & Bonomo, R. A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr013 · Cited by 63
Walkty, A. J., Lagacé-Wiens, P. R. S., Adam, H. J., Baxter, M. R., Karlowsky, J. A., Mulvey, M. R., McCracken, M., & Zhanel, G. G. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.10.003 · Cited by 63
Diagnosis of Ventilator-Associated Pneumonia
Kollef, M. H. (2006) · New England Journal of Medicine · doi:10.1056/nejme068231 · Cited by 63
Ige, O., Adesanmi, A., & Asuzu, M. (2011) · Nigerian Medical Journal · doi:10.4103/0300-1652.93796 · Cited by 78
“2 (20) Staphylococcus aureus 2 (20) Pseudomonas aeruginosa 2 (20) Pseudomonas spp.”
BackgroundRat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology
Russo, T. A., Beanan, J. M., Olson, R., MacDonald, U., Luke, N. R., Gill, S. R., & Campagnari, A. A. (2008) · Infection and Immunity · doi:10.1128/iai.00269-08 · Cited by 62
“Mortality rates associated with Acinetobacter infection range from 19 to 54% ( 16 ).”
BackgroundKao, D. J., & Hodges, R. S. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00825.x · Cited by 65
“Received 5 March 2009, revised 21 April 2009 and accepted for publication 28 April 2009 Pseudomonas aeruginosa is an opportunistic pathogen and a major cause of nosocomial infections (1).”
BackgroundAcinetobacter pneumonia: a review.
Hartzell, J. D., Kim, A. S., Kortepeter, M. G., & Moran, K. A. (2007) · PubMed · Cited by 62
Boyd, N. K., & Nailor, M. D. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.11.1073 · Cited by 64
“resistance to imipenem and ceftazidime, respectively.(10) The risk of acquiring MDR isolates and occasionally pandrug-resistant (i.”
BackgroundInfluentialRussell, C. J., Shiroishi, M. S., Siantz, E., Wu, B. W., & Patino, C. M. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0202-8 · Cited by 61
“Use of broadspectrum antibiotic therapy against gram-negative bacterial causes of nosocomial ICU pneumonia have been associated with increased bacterial antibiotic resistance rates and selection for more virulent pathogens [4].”
BackgroundInvolvement of a 1-Cys Peroxiredoxin in Bacterial Virulence
Kaihami, G. H., de Almeida, J. R. F., dos Santos, S. S., Netto, L. E. S., de Almeida, S. R., & Baldini, R. L. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004442 · Cited by 62
Zaha, D. C., Kiss, R., Hegedűs, C., Gesztelyi, R., Bombicz, M., Muresan, M. E., Pallag, A., Zrinyi, M., Páll, D., Vesa, C. M., et al. (2019) · BioMed Research International · doi:10.1155/2019/2510875 · Cited by 71
“Antibiotic resistance was discovered with the discovery of antibiotics, and a significant number of the analysed strains isolated from food products showed resistance to different antibiotic classes and the molecular techniques revealed that many of these possess either one or multiple genes that confer resistance to…”
The Acinetobacter baumannii Znu System Overcomes Host-Imposed Nutrient Zinc Limitation
Hesse, L. E., Lonergan, Z. R., Beavers, W. N., & Skaar, E. P. (2019) · Infection and Immunity · doi:10.1128/iai.00746-19 · Cited by 59
“Acinetobacter baumannii is a Gram-negative pathogen that causes pneumonia, sepsis, wound, and burn infections (1).”
BackgroundAbdelraouf, K., Kabbara, S., Ledesma, K. R., Poole, K., & Tam, V. H. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr105 · Cited by 59
Vigil, P. D., Wiles, T. J., Engstrom, M. D., Prasov, L., Mulvey, M. A., & Mobley, H. L. T. (2011) · Infection and Immunity · doi:10.1128/iai.05713-11 · Cited by 64
Wang, Y., Mi, Z., Niu, W., An, X., Yuan, X., Liu, H., Li, P., Liu, Y., Feng, Y., Huang, Y., et al. (2016) · Future Microbiology · doi:10.2217/fmb.16.11 · Cited by 59
El-Mahdy, R. H., & El-Kannishy, G. M. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s222329 · Cited by 59
“aeruginosa is a rising health problem that limits the options for treatment and prolongs hospitalization.(21) In our study, MDR and XDR P.”
BackgroundJones, R. N., Kirby, J. T., & Rhomberg, P. R. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.01.017 · Cited by 59
“These MYSTIC Program results compliment those generated in other geographic networks such the government-based studies in the United States (Fridkin et al., 2001; Gaynes and Edwards, 2005) and Europe (Cornaglia et al.”
BackgroundResultDeckers, D., Vanlint, D., Callewaert, L., Aertsen, A., & Michiels, C. W. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.00589-08 · Cited by 59
The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia
Camins, B. C., Marschall, J., DeVader, S. R., Maker, D., Hoffman, M. W., & Fraser, V. J. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.877 · Cited by 58
“1 Caucasian 60 (65) 50 (54) Other 7 (7) 1 (1) Residence: Home 55 (59) 79 (85) <0.”
Zhou, Q., Li, K., Wang, K., Hong, W., Chen, J., Chai, J. L., Yu, L., Si, Z., & Li, P. (2024) · Science Advances · doi:10.1126/sciadv.adp6604 · Cited by 58
PcrV antibody–antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice
Song, Y., Baer, M., Srinivasan, R., Lima, J. D. S., Yarranton, G. T., Bebbington, C. R., & Lynch, S. V. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1509-2 · Cited by 58
Feng, W., Sun, F., Wang, Q., Xiong, W., Qiu, X., Dai, X., & Xia, P. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2016.11.012 · Cited by 69
Fu, L., Huang, M., Zhang, X., Yang, X., Liu, Y., Zhang, L., Zhang, Z., Wang, G., & Zhou, Y. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.01.030 · Cited by 58
Tigecycline: in-vitro performance as a predictor of clinical efficacy
Hawkey, P. M., & Finch, R. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01621.x · Cited by 65
“and Escherichia coli [1].”
Sharma, V., Das, R., Mehta, D. K., Gupta, S., Venugopala, K. N., Mailavaram, R. P., Nair, A. B., Shakya, A. K., & Deb, P. K. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116674 · Cited by 57
Advances in MRSA drug discovery: where are we and where do we need to be?
Kurosu, M., Siricilla, S., & Mitachi, K. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.807246 · Cited by 64
“, staphylococci, pneumococci, vancomycin resistance in enterococci and mycobacteria) have achieved prominence in last 15 years [1-8].”
Background
Metadata
- Authors
- Weinstein, R. A., Gaynes, R., Edwards, J. R., & System, N. N. I. S.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-15
- Volume
- 41
- Issue
- 6
- Pages
- 848-854
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2151958462
- Cited by
- 1,404
- References
- 26
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 37 · 2023: 56 · 2022: 73 · 2021: 80 · 2020: 66 · 2019: 78 · 2018: 66 · 2017: 74 · 2016: 86 · 2015: 89 · 2014: 85 · 2013: 95 · 2012: 85
- FWCI
- 38.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Keywords
- nosocomial infections, Gram-negative bacilli, intensive care unit, surgical site infection, urinary tract infection, bloodstream infection, Acinetobacter, antimicrobial resistance, epidemiological trends
- MeSH terms
- Cross Infection, Gram-Negative Bacteria, Humans, National Health Programs, Population Surveillance, Surgical Wound Infection, Time Factors, United States, Urinary Tract Infections, Gram-Negative Bacterial Infections, Pneumonia, Bacterial, Sepsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.